Led · Series A · Oct 2025

MediView XR is a Cleveland-based med-tech company commercializing an augmented-reality ecosystem that fuses pre-operative CT data with live ultrasound to give clinicians ‘X-ray vision’ during interventions. Its FDA-cleared XR90 platform projects a 3D model of a patient’s internal anatomy directly onto the body, enabling head-up, hands-free guidance for biopsies, tumor ablations, injections, and other image-guided procedures. The system reduces physicians’ cognitive load by eliminating the need to translate 2D images into 3D mental maps and supports remote collaboration among care teams. MediView’s technology originated from Cleveland Clinic intellectual property and is positioned to become a new standard for less invasive care. With fresh capital, the company plans to accelerate commercial roll-out, expand industry partnerships, pursue additional regulatory approvals, and deepen AI-driven product development. Operational capacity will be scaled to meet increasing global demand. No revenue or user metrics were disclosed in the article.

Participated · Series A · Dec 2023

Laza Medical is developing an AI-powered robotically-assisted imaging solution for cardiovascular interventions. The product is designed to optimize procedural workflows and elevate the standard of imaging for these procedures. The company is a Shifamed portfolio company based in Los Gatos, CA. It raised $36M in a Series A to accelerate product development and further expand the team. Laza also announced the appointment of Pablo Garcia as General Manager. Garcia previously served as Vice President of Digital Solutions for Johnson & Johnson and was the technical co-founder of Verb Surgical, a venture later acquired by Johnson & Johnson in 2020.

Led · Series A · Oct 2023

Nucleus RadioPharma manufactures radiopharmaceuticals and manages the time-sensitive logistics required to deliver those radioactive cancer therapies to hospitals before they decay. Founded in late 2022 and launched in 2023 with a $56 million Series A, the company opened its Rochester manufacturing facility on the Mayo Clinic campus and plans a second regional hub outside Philadelphia. Its strategy centers on expanding regional manufacturing capacity to address supply-chain bottlenecks caused by short half-lives of radioactive isotopes. The recent $50 million financing from OrbiMed will fund further expansion at Rochester and construction of the Philadelphia-area site. Nucleus currently employs 56 full-time staff and is hiring as it ramps toward full operations, aiming to have the new regional center operational by 2028.

Participated · Series B · Jun 2022

Centerline Biomedical is a private medical technology company that commercializes vascular navigation technology. Founded in 2014 as a spinoff of the Cleveland Clinic, the company traces its research, development and design history to the Clinic's Lerner Research Institute Heart and Vascular Institute. Its core product is the IOPS platform, developed for vascular navigation. The IOPS platform can also be used for predictive modeling, clinical decision support, global healthcare analytics and the education and training of future surgeons and interventionists. Centerline announced the closing of a $33 million Series B equity financing led by Cleveland Clinic, with participation from GE Healthcare, RIK Enterprises, JobsOhio, Jumpstart Ventures and G2 Group Ventures. The company is based in Cleveland, OH. Centerline Biomedical is a Cleveland Clinic spinout commercializing the IOPS™ platform for interventional imaging. The platform is designed to improve patient and caregiver safety, reduce procedure time, and limit harmful radiation and contrast dye. It also aims to lower costs for healthcare systems while improving access to care. The company raised $10M in financing to enhance its team and accelerate commercialization. Limited launch commercialization was planned for Q2 2020, with a full launch in the second half of 2020. Centerline is hiring key talent, including a Head of R&D and Head of Operations, to support rollout. Centerline Biomedical develops a proprietary surgical vascular navigation system based on research from the Cleveland Clinic’s Heart & Vascular Institute. The technology aims to reduce radiation exposure to patients and caregivers while giving surgeons a GPS-like tool to improve safety and accuracy. The platform first targets the endovascular aneurysm repair market and the company plans to address a variety of additional vascular procedures. Centerline intends to use recently raised funds to advance the system to the next phase of development and continue testing. The company was founded in November 2014 and is led by CEO William Fuller. It is based in Cleveland, OH.

Led · Equity · May 2022

Pulsenmore develops a self-operated prenatal home ultrasound solution consisting of a handheld device that docks with a smartphone, a patient mobile app, a clinician web application, and a software API for health-record integration. The company's flagship fetal ultrasound product is CE-marked for Europe and approved in Israel, and clinical studies in the U.S. are underway as part of efforts to secure FDA clearance. Pulsenmore was founded in 2014 by CEO Dr. Elazar Sonnenschein and is traded on the Tel Aviv Stock Exchange (TASE: PULS). Its platform has been implemented across Israel in partnership with Clalit Health Services, and physicians at Sheba Medical Center have used the device in a virtual hospital at the Ukraine border. Pulsenmore is also developing additional remote-monitoring applications and devices including remote follicular monitoring for IVF, and monitoring for chronic heart failure and end-stage renal disease. The company aims to enable periodic clinician-guided or app-guided home scanning to expand access to prenatal care and reduce in-person visits.